HIF1A and central nervous system cancer: In 2012, Mun et al.reported a novel HIF-1 pathway inhibitor withimproved pharmacological properties as a potential anti-glioma agent.85 The group used compound 130, whichwas previously identified through high-throughput screening as a lead.The lead modification study was initiated to overcome the limitationof the poor aqueous solubility of 130 that was pinpointedas an obstacle for the in vivo evaluations.